Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Web3 Solidity Engine, tEVM 2.0 - Ahead of Schedule

Telos Foundation

As the Goliaths of crypto continuously crash ( Solana ), fail to deliver ( Ethereum ), or live in their white papers ( Cardano ), David ( Telos ) continues to defy them all and over-deliver. The Telos story is very much a David vs. Goliath story. Why? Because Telos is tens and even hundreds of billions of dollars smaller than its peers in market cap, yet still manages to significantly lead them in speed, costs, true capacity, credible neutrality, front running protection, fair governance, and energy efficiency ( Net Zero ). The tEVM Version 1.0's capabilities are already a quantum leap ahead of its peers and are clearly demonstrated in this video. Now, less than a year later, version 2.0 is set to elevate the tEVM's performance further. Jesse Schulman (Lead Architect and TCO), alongside Kersten Wirth (Program Manager), will be providing detailed insights into the development of Telos EVM 2.0. This hybrid "Super-Node" solution will be even easier to operate and integrate than the previous version, offer top-notch history management, and tie in with the best available Ethereum clients. The dev-duo will also be discussing the many benefits and successes of the existing tEVM Version 1. Since its launch, the tEVM’s ecosystem is closing on six months of strategic growth. On the DeFi side, it has already launched multiple Dex/AMMs, Price Oracles, Farming dApps, multi-Chain bridges, Lending dApps, and everything else that a vibrant DeFi ecosystem requires to level up its TVL and end-user occupancy. Telos’ TVL is now where the market cap leading chains were not long ago but with far superior governance, no front running, credible neutrality, true decentralization, and an ESG compliant EVM that is several multiples faster. In utopian fashion, Telos’ ecosystem is now ready to scale its occupants and its TVL simultaneously. About Telos Live since 2018, Telos Blockchain (ticker: TLOS) is a third-generation smart contract platform that offers compatibility with Solidity, Vyper, and Native C++ smart contracts. Telos provides full EVM/Solidity support with fixed low-cost gas fees and no front running and, more uniquely, offers a path to fee-less transactions via its robust native C++ smart contract support. Even while operating as a Net Zero Blockchain, Telos still sustainably supports hundreds of millions of transactions per day, produces blocks in 0.5 second intervals (on a first-in-first-out basis, eliminating front running on the network), and securely validates transactions via a credibly neutral and globally decentralized block producer network. As a result, the Telos blockchain has the throughput needed to facilitate and scale the thriving Metaverse / Web 3.0 landscape better than any other blockchain in existence. Its performance is unrivaled in the industry and was purpose-built to offer speed, scalability, cost-effectiveness, credible decentralization, and end-user fairness. Telos harnesses its power by utilizing tight C++ on the frontend and a custom WASM runtime environment on the backend. About The Foundation The Telos Foundation is a Decentralized Autonomous Organization established as a promotional and funding body to advance the Telos Blockchain Network and provide support to network applications. Not investing advice. Contact Details The Team hello@telosfoundation.io Company Website https://www.telos.net/

May 04, 2022 01:00 PM Eastern Daylight Time

Video Image

Altais Names Nishant Anand, M.D., as President and CEO

Altais

Altais, a healthcare services and technology company, today announced the appointment of Nishant Anand, M.D., F.A.C.E.P., as its new president and CEO, effective May 31, 2022. In this role, Dr. Anand will lead the three-year-old company that is pioneering integrated, scalable health technology solutions and transformative business models designed to enhance the patient experience, improve health outcomes, reduce cost and drive professional gratification among physicians. Dr. Anand will report directly to the Altais Board of Directors. He succeeds Altais founding President and CEO Jeff Bailet, M.D., who is retiring. “We are excited to welcome Dr. Anand to steer Altais into its next phase of growth,” said Dr. Toluwase Ajayi, Altais board member and medical director of palliative medicine at Scripps Mercy Hospital in San Diego. “His background as a board-certified physician with extensive strategic business experience makes him the perfect leader to advance Altais’ mission to cultivate the well-being of physicians, patients and the entire clinical community.” Dr. Anand comes to Altais from BayCare Health System in Florida, where he has served as executive vice president and chief medical officer since 2018. In that role, Dr. Anand had full profit and loss accountability for the physician group, a strong clinical leadership role for the system of 15 hospitals and an expanded scope of responsibility in response to the pandemic. Before BayCare Health System, Dr. Anand served as chief transformation officer and chief medical officer for population health at AdventHealth System, as well as chief medical officer to the entire Banner Health Network. Over the course of his career, he has led population health initiatives and accountable care organizations in multiple roles. Dr. Anand currently serves on the National Quality Foundation MAP Committee, a joint committee reporting to the U.S. Department of Health & Human Services and Centers for Medicare and Medicaid Services, as well as on the American Hospital Association Regional Policy Board. He has authored several peer-reviewed publications and has received numerous awards for clinical competency, his work with underserved populations, patient satisfaction and innovation. “I am thrilled to join Altais as the company leads the way in next-generation clinical services and support to physicians and communities throughout California,” said Dr. Anand. “The stresses on healthcare professionals and health systems have only escalated in recent years. Altais is uniquely positioned to provide solutions that enable independent physicians to focus on what they’ve always wanted to do, which is to provide excellent patient experiences and improved health outcomes. Personally, I am also looking forward to returning to the San Francisco Bay Area.” Dr. Anand is a board-certified emergency medicine physician, who earned his medical degree from the Mayo Medical School in Rochester, Minnesota, and completed his residency training in emergency medicine at Stanford/Kaiser Emergency Medicine Program. He has served on the faculty of the University of Central Florida College of Medicine, as well as the University of Arizona College of Medicine. Dr. Anand also served as a team doctor for the San Francisco 49ers. *** About Altais Altais is a healthcare services company that helps physicians and the clinical community maximize the health and well-being of their patients in an affordable and sustainable way. Altais has two divisions. Altais Clinical Services offers a range of affiliation and employment models for physicians and high-quality, affordable care for patients. Altais Health offers a broad platform of clinical support tools and technology, along with high-touch support. Ultimately, Altais seeks to enhance the vibrancy of physician practice and strengthen the heart of medicine – physicians connecting with patients and providing personalized, high-quality care. For more information about Altais, please visit www.altais.com. ### Contact Details Robin Carr +1 415-971-3991 altais@landispr.com Company Website https://altais.com/

May 04, 2022 03:12 AM Pacific Daylight Time

Image

Hong Kong Baptist University joint research reveals that gut microbial enzymes reactivate triclosan which induces colitis

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 3 May 2022 - A Hong Kong Baptist University (HKBU) collaborative research study has revealed that certain gut microbial enzymes mediate the reactivation of triclosan (TCS) from its inactive glucuronide metabolite. TCS is an antimicrobial agent commonly used in a wide range of consumer products, and it is associated with the development of colitis. Professor Cai Zongwei, Chair Professor of the Department of Chemistry and Director of the State Key Laboratory of Environmental and Biological Analysis at HKBU, points out that according to the research results specific gut microbial enzymes drive the conversion of TCS metabolites to TCS which increases the chance of developing colitis. The research results have been published in Nature Communications, an international scientific journal. Mechanism of TCS exposure leading to colitis previously unclear TCS is widely used as an antimicrobial agent in consumer products such as toothpaste, mouthwash, hand sanitisers, cosmetics and toys. It is a major environmental contaminant, and it has been shown that TCS exposure increases the risk of colitis. Once TCS enters the human body, it is rapidly metabolised to form the biologically inactivemetabolite TCS-glucuronide (TCS-G), which is easily eliminated from the body. Due to this characteristic, the mechanism of how environmental exposure to TCS leads to gut toxicity in the human body has previously remained unclear. To answer this question, a research team co-led by Professor Cai Zongwei, Chair Professor of the Department of Chemistry and Director of the State Key Laboratory of Environmental and Biological Analysis at HKBU; Professor Matthew R Redinbo from the University of North Carolina at Chapel Hill; and Professor Zhang Guodong from the University of Massachusetts Amherst conducted a research study based on the hypothesis that certain gut microbial enzymes act on TCS-G in the gut, leading to the reactivation of TCS and the subsequent development of colitis. TCS concentration uniquely high in the gut To begin with, the research team sought to determine whether the gut has a different TCS metabolic profile compared to other body tissues. A group of mice were fed food that contained TCS. After four weeks, it was found that the biologically inactive TCS-G was dominant in their liver, bile, heart and small intestine, while the colitis-inducing TCS was dominant in the gut (cecum and colon). The results showed that the gut has a uniquely high concentration of TCS compared to other body tissues. The research team then analysed the relationship between TCS-containing products and the concentration of TCS in the human body. In a group of human subjects who used TCS-containing personal care products for four months, both TCS and TCS-G were detected in their stool and urine samples, with TCS being dominant in stool and TCS-G being dominant in urine. However, TCS and TCS-G were not detected in the control group who used TCS-free personal care products. The results showed that the use of TCS-containing products leads to a high level of TCS, specifically in the human gut. Gut microbiota significant in TCS-G conversion The question remains why the human gut has a uniquely high TCS concentration. To answer this, the research team put forth the hypothesis that gut microbiota participate in the conversion of TCS-G to TCS, leading to the accumulation of TCS in the gut. To test this hypothesis, the researchers observed that in an in vitro setting, cultured gut bacteria from both mice and humans were able to catalyse the conversion of TCS-G to TCS. To investigate whether the same phenomenon appears in an in vivo setting, the research team found that the inhibition of gut bacteria from mice by applying an antibiotic treatment almost reduced the concentration of TCS in their guts by half, and it increased the concentration of TCS-G by six-fold. The results affirmed that gut microbiota play a significant role in the conversion of TCS-G to TCS in the gut. Specific enzymes catalyse TCS-G conversion To investigate the mechanism by which gut microbiota catalyse TCS-G conversion, the research team focused on the intestinal β - glucuronidase (GUS) enzymes produced by gut bacteria in both mice and humans, because they have been shown to catalyse a wide range of metabolite conversions. Using a series of screening techniques, two types of GUS, namely “Loop 1” and “flavin mononucleotide (FMN)-binding” GUSs, were found to be most effective at converting TCS-G to TCS in vitro. The research team then applied a GUS inhibitor, a drug that inhibits the function of Loop 1 and FMN-binding GUSs, to TCS-exposed and TCS-free mice. It was found that the GUS inhibitor could curb the conversion of TCS-G to TCS by the GUS enzymes. Colitis in TCS-exposed mice was also relieved after the application of the GUS inhibitor. The results support the notion that specific microbial GUS enzymes drive the conversion of TCS-G to TCS, and as a result, the chance of developing colitis is increased. More stringent TCS controls needed Professor Cai said: “Our research results clearly defined the mechanism by which gut microbiota are involved in the metabolism and toxicology of TCS, and the study offers a way to prevent the development of colitis following environmental exposure to chemicals. “Regulatory bodies should consider imposing more stringent controls on the use of TCS. Although the US Food and Drug Administration (FDA) banned the marketing of TCS in over-the-counter antiseptic products in 2016, the chemical remains approved for use in a wide range of products. Transparency on TCS ingredients in product labelling and illustrations should also be improved so that consumers can be aware of the potential risks and make informed choices.” #HongKongBaptistUniversity #HKBU Contact Details Winnie Shum of the Communication and Public Relations Office +852 3411 5262 hkbunews@hkbu.edu.hk Company Website https://www.hkbu.edu.hk/

May 03, 2022 09:00 AM Eastern Daylight Time

Image

CognitiveCare Inc. Receives a Grant of Nearly $1 Million to Advance Maternal and Fetal Health

CognitiveCare

CognitiveCare, a Healthcare AI startup and pioneer in maternal and infant health, today announced it has received a $965,871 grant from the Bill & Melinda Gates Foundation to provide antenatal risk stratification AI support for the ARC’s pregnancy surveillance efforts. According to the World Health Organization (WHO), global maternal mortality is an unacceptably high 810 deaths per day, primarily from preventable or treatable causes. Further, 10–15% of all infants born are preterm and are at increased risk of morbidity and mortality. As part of this grant, CognitiveCare will detect and quantify propensity for critical adverse outcomes during antepartum, intrapartum, and postpartum stages, by leveraging CognitiveCare’s Maternal Infant Health Insights & Cognitive intelligence “ MIHIC ” solution. MIHIC incorporates granular insights and patterns that interplay with clinical and social determinants of health to help detect and quantify risks at individual and population levels. CognitiveCare will first validate its models with local data and will then integrate MIHIC into both the Kenya PRiSMA (western Kenya) and the Aga Khan University & VITAL Pakistan ARC sites’ existing production environments. A segment of this grant is dedicated to train the ARC sites to use MIHIC, ensuring sustainable impact. “With the foundation’s grant support, our aim is to support caregivers in understanding propensity for risk early enough to help reduce maternal and infant morbidity and mortality,” said Dr. Suresh Attili, Co-Founder and Chief Medical Officer, CognitiveCare. “Decisions on patient care rest with physicians; however, risk scores generated by MIHIC support triaging patients early. The models will further provide explainable AI functionality to help caregivers understand the ‘why’ behind each MIHIC Score TM.” “ G iven that 94% of all maternal deaths occur in low- and lower-middle-income countries, CognitiveCare is committed to ensuring that low resource settings have access to MIHIC,” said Sheena Gill, President, Americas for CognitiveCare. “With this grant, we take another important step toward our vision to eradicate maternal and infant mortality globally.” About CognitiveCare: CognitiveCare is working at the forefront of science to build the world's first comprehensive health risk quantification solution that integrates AI, advanced math, and stats at the intersection of medicine, biology, genomics and social determinants. CognitiveCare's MIHIC Score™ platform assesses propensity for risk of maternal, fetal and infant health risks categorized as antepartum, intrapartum and postpartum risk scores early in the pregnancy cycle to empower proactive care. To learn more about CognitiveCare, please visit: www.cognitivecare.com. Contact Details CognitiveCare Vivek Singh vivek@cognitivecare.com Company Website https://cognitivecare.com

May 03, 2022 08:00 AM Eastern Daylight Time

MetroPlusHealth And NYC Health + Hospitals', Dr. Eric Wei, Named to City & State's "2022 Power Of Diversity: Asian 100."

MetroPlusHealth

Eric Wei, MD, MBA, Board Member and Chair of the Quality Assurance & Performance Improvement Committee of MetroPlusHealth and Senior Vice President and Chief Quality Officer of NYC Health + Hospitals has been named to City & State’s “2022 Power of Diversity: Asian 100” list. He will be featured in a special edition of City & State published today, recognizing the most influential Asian Americans in New York. The prestigious Asian 100 list has included leaders such as Congress Member Grace Meng, State Senator John Liu, and former Presidential candidate Andrew Yang. “I am honored to be recognized by City & State, and I am proud to see the accomplishments of New York’s vibrant Asian-American community being celebrated on such a prominent platform,” said Dr. Wei. “As challenging as the last two years have been, I am grateful to be a part of a public health care system that is committed to the values of diversity and inclusion. I want to thank my amazing team at NYC Health + Hospitals, colleagues at MetroPlusHealth, and family for their unwavering support.” In addition to Dr. Wei’s achievements, he has been a strong advocate for the Asian American Pacific Islander (AAPI) community. He will be a featured speaker at a May 18 th press conference on the steps of City Hall, addressing the lack of resources and the critical importance of mental health and wellness among AAPI New Yorkers. Dr. Wei was a panelist at the Stop Anti-Asian Hate Crime Town Hall in 2021, hosted by MetroPlusHealth. He presided over the Grand Opening of MetroPlusHealth’s flagship community office in Flushing, Queens, bringing needed resources to the neighborhood’s large Asian population. “Congratulations to Dr. Wei on being recognized as City & State Diversity: Asian 100 recognition,” said Dr. Talya Schwartz, President and CEO of MetroPlusHealth. “Dr. Wei has been an incredible leader and advocate in the AAPI community, especially during the COVID-19 pandemic. His work in creating an equitable future for the health of the AAPI communities is a key component to closing the gaps in health care disparities.” “Dr. Wei is incredibly deserving of this recognition, and we are happy to celebrate this wonderful achievement with him,” said Dr. Mitchell Katz, President and CEO of NYC Health + Hospitals. “Eric’s heroic leadership during the pandemic has solidified him as one of the most influential people in this great city we are so proud to serve.” The special recognition comes at the start of Asian American Pacific Islander Heritage Month and Mental Health Awareness month. In early May, MetroPlusHealth will release the findings of a research project surveying Asian females in New York City about their mental health concerns. Additionally, MetroPlusHealth will partner with community-based organizations providing mental health services to the AAPI community. Dr. Wei will participate in video interviews with these organizations to raise awareness of seeking help to improve mental health and wellness. Dr. Wei’s focus during the pandemic included strategic planning to quadruple ICU capacity, reconfiguring emergency departments to accommodate the needs and patient volume demands and leading the patient level-loading system that moved over 850 COVID-19 patients in the first NYC wave to ensure each hospital was operating safely considering high patient volumes. He also oversaw more than $35 million in donations to the public health system to help with employee accommodations, such as meals, transportation, and childcare. The expansion of the Helping Healers Heal program supports employees’ emotional and psychological well-being. Dr. Wei is the fellowship director for the NYC Health + Hospitals Clinical Leadership Fellowship and launched Healthcare Administration Scholars Program (HASP) across 5 NYC Health + Hospitals sites. He is a practicing Emergency Medicine physician rotating through all 11 Emergency Departments in NYC Health + Hospitals. He serves as faculty for the Greater New York Hospital Association/UHF Clinical Quality Fellowship Program. Dr. Wei received his bachelor’s degree in Molecular, Cell and Developmental Biology at the University of California, Los Angeles, in 2003. He completed the combined MD and MBA program at the University of California, Irvine, in 2009. Dr. Wei completed his Emergency Medicine residency and the Healthcare Administration Scholars Program at the University of Michigan in 2013. He is certified in Lean Healthcare, Six Sigma Black Belt, and TeamSTEPPS Master Trainer. He is a fellow of the American College of Emergency Physicians. Dr. Wei was named to Modern Healthcare’s “50 Most Influential Clinical Leaders” list and Forbes 40 Under 40, both in 2021. As with many New Yorkers, the pandemic has raised the mental health challenges faced by the AAPI community during these difficult times. New York City offers free, private mental health support in Chinese, Japanese, Korean, and more than 200 languages. Support can be accessed 24/7, 365 days a year. To speak to a counselor and get access to services, call 888-NYC-WELL (888-692-9355) or text “WELL” to 65173. City & State Diversity: Asian 100 list: https://www.cityandstateny.com About MetroPlusHealth Since 1985, MetroPlusHealth Plan has built a reputation for providing access to affordable, quality health care to residents across New York City. MetroPlusHealth is the plan of choice for over 600,000 New Yorkers and has a five-star rating based on the State’s 2020 Consumer’s Guide to Medicaid and Child Health Plus Managed Care Plans in New York City. The health plan’s robust network of primary care doctors and specialists includes many independent community providers. Culturally sensitive and fluent in more than 40 languages, MetroPlusHealth’s staff is as diverse as the great city it serves. For more information about MetroPlusHealth plans, benefits, and services, visit www.metroplus.org and join the conversation at facebook.com/metroplushealth and Twitter @metroplushealth. MetroPlusHealth is a wholly-owned subsidiary of NYC Health + Hospitals, the nation’s largest public health system. About NYC Health + Hospitals NYC Health + Hospitals is the largest public health care system in the nation serving more than a million New Yorkers annually in more than 70 patient care locations across the city’s five boroughs. A robust network of outpatient, neighborhood-based primary and specialty care centers anchors care coordination with the system’s trauma centers, nursing homes, post-acute care centers, home care agency, and MetroPlus health plan—all supported by 11 essential hospitals. Its diverse workforce of more than 42,000 employees is uniquely focused on empowering New Yorkers, without exception, to live the healthiest life possible. For more information, visit www.nychealthandhospitals.org and stay connected on Facebook at https://www.facebook.com/NYCHealthSystem or Twitter at @NYCHealthSystem. Contact Details Divendra Jaffar, MetroPlusHealth 212-908-3380/646-952-3243 jaffadi@metroplus.org Company Website https://www.metroplus.org/

May 02, 2022 02:41 PM Eastern Daylight Time

Image

Youth Nicotine Vaping is a Mental Health Crisis

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/PzinsT6mmYA Two health crises among youth — a mental health crisis and a vaping epidemic — pose increasing threats to a generation of young people. A recently published study in the Journal of the American Medical Association (JAMA) shows that youth depression and anxiety doubled during the pandemic, compared to pre-pandemic estimates. Meanwhile, youth vaping remains at epidemic levels with nearly 20% of high schoolers vaping nicotine, with nearly 40% of those who use e-cigarettes, doing so on a regular basis. Truth Initiative ®, the organization behind the highly effective truth ® youth smoking, vaping and nicotine public education campaign organized a Moment of Action for Mental Health as part of its latest Breath of Stress Air effort to bust the fantasy that vaping nicotine is a stress reliever. The Moment of Action for Mental Health comes on the heels of Surgeon General Vivek Murthy issuing an advisory on the state of mental health among young people as an “urgent public health crisis,” and coincides with the on-going youth e-cigarette epidemic. According to the latest December 2021 Monitoring the Future Survey (MTF) report, nearly 20% of high school seniors used e-cigarettes in the past 30 days. A Truth Initiative survey found that 93% of e-cigarette users reported that vaping negatively affected their lives because it made them feel more stressed, depressed, or anxious, while 90% of those who quit said they felt less stressed, anxious, or depressed. Young people nationwide can text “ ACTION ” to 88709 to participate and join in the movement. Those looking to get help quitting e-cigarettes can get free and anonymous help from This is Quitting from truth. It is a free and anonymous, text-message based quit vaping program designed for young people. Teens and young adults can join for free by texting “ DITCHVAPE ” to 88709. Learn more about Truth Initiative, the Moment of Action for Mental Health and see get resources by visiting truthinitiative.org. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 02, 2022 01:00 PM Eastern Daylight Time

Video

News Release

Strawberry Gelato Delta 8 Gummies Launched By BudPop: New Delta 8 Flavor Of The Season

Blue Ribbon Group

BudPop, a Los-Angeles owned cannabis products brand, has continued to build on the fame it has garnered over the years. The company is well-known for its immense contribution to the delta-8 industry. Its edibles are high-ranking. You will find several high-quality products from this brand ranging from gummies to oils. With the launch of its delta-8 gummies, the brand's reputation has increased tremendously. These gummies are manufactured in the United States. They contain the best ingredients. Furthermore, these gummies are vegan-friendly and easy to use. You don't need to worry about your dietary preferences. The gummies do not contain animal ingredients. You will also like these D8 gummies for their cruelty-free nature. BudPop released two flavors for its mouth-watering gummies. They are Blue Dream and Strawberry Gelato. While these two flavors have hit the market hard, customers prefer the Strawberry Gelato. This is because of its taste and effects. The highly-potent gummies help you become more relaxed and calmer while facing challenging tasks. Furthermore, users feel comfortable because the product offers a fantastic alternative to smoking weed. You don't have to worry about the aftertaste of these gummies. The Strawberry Gelato flavor persists even after hours of consuming the gummies. Hence, no one will notice you used any cannabis product. You will find 25 gummies in one container of these mouth-watering gummies. Each Strawberry Gelato edible has a potency of 25 mg. One exciting feature of these gummies is that they seem smoother than other products. As per Budpop reviews & customer reviews, you will find that these gummies do not hurt your throat. Furthermore, the gummies offer a smooth transition with minimal or no side effects if consumed correctly. There are several other gummies on the market. However, BudPop's Strawberry Gelato stands out. You will notice that these gummies do not have any fillers. Furthermore, you can expect an anxiety-free experience since the product does not contain delta-9 THC. Agreeably, several users have attested to the benefits of using these gummies. In particular, users found the gummies helpful in relieving chronic pain. Another proof of safety is that these Delta 8 gummies do not have any harmful chemical substances. To further build trust with its clients, the best Delta 8 Gummy brand allows users to confirm the results from its third-party laboratory tests on the official website. If you have second thoughts about the product's quality, you can check out these reports. While scientific data is still underway, customer reviews reveal the benefits of using these gummies. Most people consider BudPop delta 8 gummies helpful against seizures and other chronic disorders. The gummies help stop attacks temporarily or permanently, depending on the usage time. Some other users noted that the product helped relieve seizure symptoms. Note, however, that not everyone consumes these gummies to relieve disorders. Some users utilize the product to enhance their overall body health. Additionally, you can use this product to obtain some therapeutic properties. BudPop uses fruit-derived pectin to make its Strawberry Gelato gummies. Their use favors everybody, especially vegans who can also consume gummies. You will also find that the brand uses hemp from the best-licensed farms in Nevada for production. These farms do not use pesticides or other harmful substances to produce hemp plants. In addition, the product does not contain genetically modified organisms (GMOs). All-natural ingredients ensure that you obtain the best benefits without any harm. BudPop uses an efficient hemp extraction process known as CO2 extraction. The extraction process is efficient because all the essential compounds get retained. Such compounds include terpenes which provide the natural flavoring in the product. What are the ingredients used to make this Strawberry Gelato stand out? The main ingredient used to produce these gummies is the hemp plant. The hemp used for production has 100% GMO-free, pesticide-free, and organic components. Furthermore, the hemp plant used undergoes the full-spectrum separation process. The full-spectrum separation process ensures that all the essential compounds get retained, including THC. Since THC is available, users get the trademark 'high' that comes with consuming cannabis. Some of the compounds you will find include cannabinoids, flavonoids, and terpenes. You will most likely find cannabinoids as natural components of the hemp plant. While the complete profile of cannabinoids includes 66 of them, a few stand out. Some of these components contain tetrahydrocannabinol (THC, cannabigerol (CBG), cannabidiol ( CBD ), and cannabinol (CBN). You will find these components helpful because they provide effects by interacting with some cannabinoid receptors in the body. The results depend on the area of the brain involved in the interaction. However, these ingredients include psychomotor performance, memory, and cognition. Furthermore, these components stimulate pleasure and reward experiences in users. Flavonoids elicit several mind-affecting and medicinal properties in users. In addition, the compound stimulates different pathways in the brain. Thus, flavonoids help control pain and provide uplifting effects to users of this product. The hemp plant contains several exclusive flavonoids such as cannflavin A, B, and C. They offer users anticancer, brain-protecting, and antioxidant properties. Terpenes are vital components in the production of these gummies. These terpenes are responsible for the unique aroma of the gummies. Furthermore, you will find that BudPop's gummies are more effective because they use terpenes. Thus, you can say that terpenes offer a better user experience. In addition, when combined with full-spectrum CBD, users obtain more potent effects. BudPop's Strawberry Gelato gummies work by stimulating the endocannabinoid system in your body. The system consists of your brain receptors essential in the cannabis experience. The compounds used in the gummies modify your brain to lift your mood and relieve pain. Furthermore, the ingredients enhance your sleep cycle, boost your energy levels, and improve other body functions. Thus, when you use this product consistently, you will get positive changes in your overall health. You will feel most of the effects of these gummies immediately after use. However, you may experience lags in results depending on individual differences. These effects usually start slowly and reach their peak before wearing off. Note that the gummies do not contain more than 0.3% THC. Thus, these gummies remain safe for consumption. Furthermore, the brand follows the 2018 Farm Bill to ensure that its product remains legal. While you may experience a slight 'buzz' during usage, you won't get too high since the THC content isn't much. Strawberries are always welcome all day. Many users have identified with gummies because of their sweet aroma and flavor. You will find that the flavor has amassed several orders more than all the other flavors. Furthermore, users love the aftertaste, which reminds them of the good old days as kids. Hence, the flavor provides benefits and ignites youthful memories of the past. You can sneak in a gummy while working without inconveniencing your colleague. You don't need to worry about the trademark scent of consuming cannabis products. Instead of that scent, your colleagues will perceive a pleasant aroma of strawberries. So far, many users believe the Strawberry Gelato is the best flavor yet from BudPop. BudPop is one of the prominent names on the list when considering edibles. With its Strawberry Gelato gummies, the brand has won the hearts of many users. The gummies are the season's flavor because they remind users of childhood memories. Asides from its pleasant aftertaste, you can derive several benefits from using this product. Firstly, you get to relax after a stressful day. But who says you can only use BudPop delta 8 gummies after a stressful day? You can use these gummies to help you navigate challenging situations in the calmest ways. Secondly, you can obtain relief from pain while using BudPop Strawberry Gelato gummies. In addition, you get to sleep better, focus more, and experience a 'safe high' with this product. Unlike many other products, this flavor ensures that your satisfaction is guaranteed. With its state-of-the-art ingredients, you get all the benefits of enjoying cannabis. Another good news is that you can safely experience the effects of cannabis without disturbing the public. Since the product gives off a sweet strawberry flavor, it is challenging to inconvenience anyone. While you enjoy the benefits of these gummies, you must ensure to stick to the manufacturer's instructions. As a newbie, consume half a gummy to gauge your tolerance level. If you feel you can tolerate more, take the remainder and observe the effects on you. Once you have determined the perfect dosage, you can enjoy your Strawberry Gelato without issues. If you have any problems, you can reach out to the customer service team, which is always available. Contact Details Riya Tyagi +1 818-468-5567

May 02, 2022 05:27 AM Eastern Daylight Time

News Release

Tranont Announces A New Product And Changes To Compensation And Pricing

Tranont, LLC

Tranont recently brought nearly 1,000 of its Associates and Customers to the Salt Palace Convention Center in Salt Lake City for the Tranont Convention 2022. Roaring crowds welcomed product, shipping, and other announcements. “The theme of this convention was ‘Level Up,’” offered Tranont President Scott Bland. “We designed these updates to promote strength and develop leadership, and to more effectively reward Associates who are growing and taking their Tranont businesses to the next level.” The primary announcement—unique to the networking industry—has people still buzzing: Tranont will be the first company of its kind to offer cryptocurrency as a means to generate income and reward business-building activities, like having a monthly Subscription order, attending Tranont events, and more. More information on Tranont Coin will come in June 2022. Other announcements included the pre-launch of Replenish, a powerful nighttime beverage with seven mushrooms, plus ashwagandha and fulvic acid. These distinctive botanicals work synergistically to help support body function, promote restful sleep and stress management, and improve skin health. It will be available for regular purchase in May 2022. Other updates include free shipping on all orders over $100, a Buy More/Save More shopping program that offers additional savings, and discounted pricing for all Subscription customers. Tranont also introduced a money-back guarantee of satisfaction on wellness products. The third of Tranont’s three pillars—Health, Wealth, and Community—had attendees supporting the building of more than 1,000 craft kits that were delivered to a local children’s hospital. All enhancements help position Tranont for growth. “Change is an integral part of our business,” continued Bland. “This isn’t about reacting to the current economy; we’re looking ahead and leading with change as we meet the future with the most powerful product line, most competitive pricing, and most rewarding compensation plan in the industry.” About Tranont Based in the heart of the Wasatch Mountains in Utah, Tranont is a health- and wealth-education company providing instruction, products, services and entrepreneurial opportunity. Tranont supports neighbors helping neighbors to improve their health, to create more wealth, and to leave a lasting impact in their communities. Inc. magazine has recognized Tranont on its lists of fastest-growing companies for the past three years running. The company, begun in 2013, has a stated mission to impact 1 billion lives for good in its first 30 years. For more information, please visit Tranont.com. Contact Details Tranont, LLC Dave Webb - Director of Communications +1 801-916-9322 dave@tranont.com Company Website https://tranont.com/

April 29, 2022 03:50 PM Mountain Daylight Time

Letter Outlines Significant Concerns with House Committee’s Unreleased Report

United Network for Organ Sharing

Today, United Network for Organ Sharing (UNOS) Board President Matthew Cooper, M.D. and Board Vice President Jerry McCauley, M.D. sent a letter to the Chair of the House Committee on Oversight and Reform, sharing their concerns about a report that the committee chose not to release. After receiving an embargoed copy of the report, media outlets began inquiring about the contents. Based on their questions, the report appeared to draw inaccurate conclusions about the nation’s organ donation and transplant system based on a fundamental misunderstanding of donation data and the organ procurement process. The UNOS letter outlines concerns about the impact such a report could have on patients and expressed disappointment in the lack of basic knowledge outside critics involved in the report’s development appear to have about organ donation and recovery. The letter also thanked members of the committee for halting the report’s release. Below are excerpts from the letter: “It is our understanding that the report concludes that some of the nonprofits responsible for facilitating organ donations, organ procurement organizations (OPOs), are missing the “vast majority” of opportunities for donation. Based on the statistics shared with us by the press, it appears as though the report assumes that every person who has died in a hospital is a “potential donor,” even if they were not medically cleared to be an organ donor. In fact, less than 1% of all deaths in the U.S. occur in ways clinically compatible with organ donation; people who die of cancer, sepsis, certain infectious diseases, or organ failure are ruled out for donation by the OPO using medical criteria established by transplant physicians for the safety of the potential recipient.” “The effect of recommending that organ procurement organizations should seek donation authorization for every in-hospital death would have OPOs approaching grieving families about organ donation – even when the OPO had already determined that that donation was not a clinical possibility. Giving false hope to families at such a difficult time wouldn’t just be inefficient, it would be cruel.” “This is not the first time that the organ donation and transplant system has been the subject of criticisms based on inaccurate data. A small group of critics has been circulating a series of op-eds, self-funded “research,” and out-of-context references to paint the world’s highest-performing organ donation and transplant system as ineffective.” The letter closes with Cooper and McCauley sharing the ongoing successes of the nation’s donation and transplantation system and referring to the thoughtful recommendations offered in the recently released National Academies of Science, Engineering, and Medicine (NASEM) report as a blueprint for continuing to improve the system, address challenges, and best serve patients. Read the full letter here. ### About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

April 29, 2022 10:13 AM Eastern Daylight Time

1 ... 230 231 232 233 234 ... 311